Twenty-seven patients with advanced multiple myeloma received high-dose therapy with 220 mg/m 2 i.v. melphalan (HDM220) followed by autologous stem cell transplantation. At the time of HDM220, nine patients had primary refractory disease and 18 were in relapse after having responded to prior high-dose therapy. No toxic deaths were observed. The major adverse sideeffect was grade 4 mucositis in 63% of patients. Two patients experienced reversible paroxysmal atrial fibrillation after HDM220. For the whole group of patients, the actuarial 3-year overall survival (OS) and event-free survival (EFS) are 36.1 and 16.9%, respectively. The probability of OS and EFS was significantly lower in patients treated for refractory relapse (22.9 and 0% at 2 years, respectively) as compared to primary refractory patients (66.7 and 64.3% at 2 years, respectively) or patients treated for chemosensitive relapse (42.9% at 2 years) (P ‫؍‬ 0.0001). Low ␤2-microglobulin and CRP levels at the time of HDM220 were associated with a better OS and EFS. Our data suggest that HDM220 followed by ASCT should be considered in patients with primary refractory disease or chemosensitive disease relapsing after prior intensive therapy. Keywords: myeloma; high-dose chemotherapy; melphalan; autologous stem cell transplantation The outcome of patients autografted for newly diagnosed multiple myeloma (MM) seems to be superior to that seen with those receiving conventional chemotherapy.
The outcome of patients autografted for newly diagnosed multiple myeloma (MM) seems to be superior to that seen with those receiving conventional chemotherapy. 1, 2 However, the optimal conditioning regimen is still unknown, and most patients eventually relapse following autotransplantation. Complete response (CR) rate was only 22% and probability of event-free survival (EFS) for 5 years was 28% following 8 Gy total body irradiation (TBI) and 140 mg/m 2 melphalan (HDM140) in the French trial comparing conventional and high-dose therapy. 1 Two hundred mg/m 2 melphalan (HDM200) without TBI is a valuable alternative and is the highest dose usually infused before autotransplantation. 2, 3 Taking into account the clear relationship between dose and response established in patients treated with melphalan for MM, 4, 5 we have tried to increase the dose of melphalan infused in order to increase the CR rate. Thus, we have shown in a pilot study that 220 mg/m 2 melphalan (HDM220) followed by autologous stem cell transplantation (ASCT) is feasible. 6 As expected in this trial, the area under the plasma concentration curve with HDM220 was higher compared with HDM140 or HDM200, and we described an encouraging response rate in eight out of nine patients with advanced MM, heavily pretreated. These preliminary results needed to be confirmed in a larger series of patients with a longer follow-up. We show here the updated results of HDM220 followed by ASCT in 27 patients with advanced MM.
Patients and methods
Twenty-seven patients with advanced MM were entered into this study between February 1995 and October 1997 (Table 1) . At the time of HDM220, nine patients had never responded to either standard melphalan-prednisone chemotherapy nor to vincristine-adriamycin-dexamethasone (VAD) and were considered as primary refractory. One of them also received one course of HDM140 without any response. The other 18 patients were in relapse after having responded to a prior high-dose therapy; this relapse was 
Autologous stem cell transplantation
In all cases peripheral blood stem cells were collected before HDM220 after G-CSF priming (10 g/kg/day ϫ 6 days) in steady-state. Melphalan 220 mg/m 2 was administered by infusion over 30 min, with forced diuresis. Peripheral blood stem cell transplantation was carried out 2 days after the infusion of melphalan (median dose of CFU-GM/kg: 12.3 ϫ 10 6 , range 1.7-55.3, and of CD34/kg: 2.5 ϫ 10 4 range 0.8-8.1).
Supportive therapy
All patients were treated in single rooms with positivepressure ventilation. Blood products transfused were not screened for cytomegalovirus antibody but were leukocytedepleted using filters. An attempt was made to maintain the hemoglobin over 8 g/dl and platelets over 20 ϫ 10 9 /l. Fever during the neutropenic phase was treated with broad-spectrum antibiotics and amphotericin as necessary. Granulocyte colony-stimulating factor (5 g/kg/day) was given in all cases after ASCT.
Grading of toxicity
High-dose related toxicity was graded according to the WHO scale.
Evaluation of response
Response to HDM220 was assessed according to the criteria defined by Gore et al. 7 Patients were regarded as having achieved CR when no paraprotein was measurable by serum protein electrophoresis, when no Bence-Jones proteinuria was detectable on urine electrophoresis, and when bone marrow aspiration showed less than 5% plasma cells. Patients were in partial remission (PR) if there was a 50% decrease in M-component or bone marrow infiltration. All other results were regarded as failures.
Statistical analysis
The data were analyzed as of 1 May 1998. Actuarial overall and event-free survival curves were estimated using the method of Kaplan and Meier, and the distributions compared using the log-rank test. Overall survival (OS) was calculated for all patients from the date of ASCT to the date of death or last follow-up if alive. Event-free survival (EFS) was calculated from the date of documented failure, disease progression, relapse, death from any cause. For the purposes of EFS and disease progression, patients who had active disease at the time of ASCT which never responded were plotted as failures from the time of transplant. The following variables were analyzed in multivariate fashion using a Cox proportional hazards model for their effect on the probabilities of OS and EFS: Ig isotype, albumin, Creactive protein and ␤2-microglobulin (B2M) levels at the time of HDM220, disease status at time of HDM220 (primary refractory, refractory relapse, chemosensitive relapse), time to relapse after the preceeding transplant (Ͻ or у12 months).
Results

Toxicity of HDM220
No toxic deaths were observed. The median duration of hospitalization was 24 days (range, 16 to 35). The median durations of neutropenia Ͻ 0.5 ϫ 10 9 /l and Ͻ1 ϫ 10 9 /l were 10 days (range 7-13) and 11 days (range 7-17), respectively. The median time to an unsupported platelet count Ͼ25 ϫ 10 9 /l was 15 days (range 4-not reached). Five patients experienced prolonged thrombocytopenia: two patients never achieved a platelet count of 25 ϫ 10 9 /l, and three others required platelet transfusions for Ͼ3 months after ASCT. All five patients had been heavily pretreated before stem cell collection and HDM220, with regimens including TBI or busulfan plus HDM140. Seventeen patients (63%) experienced severe grade 4 mucositis for a median duration of 8 days (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . No liver, renal or pulmonary toxicity was observed. Two patients (7.4%) experienced paroxysmal atrial fibrillation successfully treated by amiodarone therapy. Despite anti-emetic therapy with setrons, all patients experienced nausea and vomiting, grade 2 in 16 and grade 3 in 11 cases. All patients had grade 3 complete alopecia which began 2 weeks after melphalan therapy.
Outcome
Initial response to HDM220 was evaluated 3 months after ASCT, except in one patient who experienced fulminant progression of MM after ASCT and died on day 40. Twenty-three out of 27 patients (85%) experienced a response. Seven patients (26%) achieved CR, and 16 (59%) achieved PR. In 3/7 complete responders, CR was confirmed by immunofixation. Four out of 27 patients did not respond to HDM220. At the time of analysis, with a median follow-up of 15 months (range 7-36), 14 patients are alive in PR or CR, six patients are alive with progressive disease, seven died from progressive disease. For the whole group of patients, the actuarial 3-year OS and EFS are 36.1% (Ϯ17.8%) and 16.9% (Ϯ13.4%) respectively (Figure 1) . The median OS and EFS from ASCT are 31 and 12 months, respectively (Figure 1 ). The probability of OS and EFS was significantly lower in patients treated for refractory relapse (22.9% and 0% at 2 years, respectively) as compared with primary refractory patients (66.7 and 64.3% at 2 years, respectively) or patients treated for chemosensitive relapse (42.9% and 42.9% at 2 years, respectively) (P ϭ 0.0001) (Figures 2 and 3) .
Univariate analysis showed that two parameters, high CRP (Ͼ4 mg/l) and high B2M (Ͼ2.5 mg/l), were associated with a lower probability of both OS and EFS. The projected OS and EFS at 3 years were 50 and 66.7% for the patients transplanted with low B2M and CRP levels vs 27 (P ϭ 0.08) and 20.9% (P ϭ 0.05) for the others, respectively. However, in the group of 19 patients who received a prior intensive therapy, the interval between the first highdose therapy and HDM220 (Ͻ or у12 months) did not affect the outcome (P ϭ 0.74).
Discussion
This pilot study confirms that HDM220 is feasible provided that ASCT is performed. No toxic deaths occurred in our series. Nevertheless, we observed three significant clinical problems after HDM220: severe mucositis, delayed platelet engraftment, and cardiac arrhythmia. Grade 4 mucositis occurred in Ͼ60% of the cases. This toxicity, although reversible in all cases, was not reported by Cunningham et al 3 who observed only one case of grade 4 mucositis in a group of 53 patients treated with HDM200. One major difference in this latter series is that HDM was administered as consolidation in previously untreated MM, whereas our patients had been heavily pretreated before HDM220.
After HDM220 and ASCT, neutrophil recovery was rapid, but delayed platelet engraftment was observed in five patients (18.5%). This differed from Cunningham et al who found after HDM200 and ASCT a median time of 13 days (range, 5-44) with a platelet count Ͻ25 ϫ 10 9 /l. Here again, disease stage probably explains this delayed platelet recovery, with a high number of patients in our series previously treated with high-dose therapy, altering the quality of the graft harvested before HDM220. 8, 9 Our series is the second to report the occurrence of paroxysmal atrial fibrillation after HDM. Recently an Italian team have described this adverse side-effect in five out of 76 patients (6.6%) treated with HDM (140 to 200 mg/m 2 ) in the absence of any detectable structural heart disease. 10 Further cases are needed to establish the possible relationship between HDM and acute cardiotoxicity.
In the present trial, we studied two categories of patients. First, patients refractory to at least two lines of conventional treatment including conventional-dose melphalan (ie primary refractory patients), and secondly, patients relapsing after a prior autologous transplant. For the first group of patients, many clinical studies have validated the hypothesis of a dose-response relationship for melphalan. 5, [11] [12] [13] [14] [15] However, the dose of melphalan used in this setting has usually varied from 80 to 140 mg/m 2 , the responses were of short duration (5 to 7 months), and the median survival time in this group of primary refractory patients was 7 to 10 months. 5, [11] [12] [13] [14] Vesole et al 15 showed that better results could be achieved in such patients with further dose intensification with HDM200 followed by PBSC transplantation.
These authors report a median OS and EFS duration of 43 and 21 months, respectively, in 67 patients, with a low mortality rate of 1.5%. Our results confirm both the feasibility and the efficacy of higher doses of 220 mg/m 2 melphalan in this setting with projected 3-year OS and EFS rates of 66.7 and 64.3%, respectively, without any toxic deaths.
In the group of patients who received prior intensive therapy and subsequently relapsed, HDM220 is only useful when the disease is chemosensitive. In refractory relapses, escalating the doses of melphalan is ineffective and probably useless, with a 0% EFS rate at 1 year. On the contrary, patients with chemosensitive disease after prior intensive therapy do fairly well with a projected 3-year survival of 42%. Similar results have recently been achieved by the group at Little Rock, showing a 4-year survival of 50% in a group of patients who have failed a previous autograft, and who subsequently received salvage ASCT after HDM140 plus 1125 cGy total body irradiation (14 patients) or HDM200 (18 patients). 16 In this trial, low CRP at the time of second transplant also influenced the transplant favorably. The same group had previously shown that two other factors, B2M and late relapse after the preceding transplant (Ͼ12 months), could favorably affect the outcome of such patients. 17 Our data confirm the predictive value of a low B2M level at the time of second transplant.
Until now, no randomized trial has shown that ASCT is the best therapeutic option in patients with MM relapsing after a prior autograft. Nevertheless our data, in addition to those of the group at Little Rock 16, 17 suggest that HDM could be useful in this setting. However, it is not currently possible to say whether the results achieved with HDM220 are superior to those achieved with HDM200. Only a randomized study could answer this question. HDM220, which is tolerable and effective, should be considered as a valuable strategy in chemosensitive patients with low CRP and B2M levels at the time of the second transplant if an adequate graft is available. Given its feasibility, it should also be considered earlier in the course of the disease in primary refractory patients, or as an alternative consolidation therapy in previously untreated patients below the age of 60. Nevertheless, due to its extrahematological toxicity (mucositis, cardiac) it could be difficult to further increase the doses of i.v. melphalan. In order to improve response rates, other therapeutic approaches are necessary, such as multicyclic dose-intensive chemotherapy supported by hemopoietic progenitors, 18 or combination of monoclonal anti-IL6 antibody with HDM220 and ASCT, and this trial is ongoing in our institution.
